Cibus (CBUS) 10-Q 4 Aug 22 2022 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2022	Aug. 03, 2022
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity File Number	001-38161
Entity Registrant Name	Calyxt, Inc.
Entity Central Index Key	0001705843
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	27-1967997
Current Fiscal Year End Date	--12-31
Entity Address, Address Line One	2800 Mount Ridge Road
Entity Address, City or Town	Roseville
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55113-1127
City Area Code	651
Local Phone Number	683-2807
Title of 12(b) Security	Common Stock (0.0001 par value)
Trading Symbol	CLXT
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		46,792,093

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 11,316	$ 13,823
Restricted cash	545	499
Prepaid expenses and other current assets	1,002	859
Total current assets	12,863	15,181
Non-current restricted cash	53	99
Land, buildings, and equipment	5,077	21,731
Operating lease right-of-use assets	13,855	0
Other non-current assets	169	183
Total assets	32,017	37,194
Current liabilities:
Accounts payable	519	1,260
Accrued expenses	262	339
Accrued compensation	2,272	2,522
Due to related parties	101	172
Current portion of financing lease obligations	246	370
Common stock warrants	688	0
Other current liabilities	413	191
Total current liabilities	4,501	4,854
Financing lease obligations	37	17,506
Operating lease obligations	13,652	0
Other non-current liabilities	68	702
Total liabilities	18,258	23,062
Stockholders' equity:
Common stock, $0.0001 par value; 275,000,000 shares authorized; 46,815,694 shares issued and 46,715,542 shares outstanding as of June 30, 2022, and 38,874,146 shares issued and 38,773,994 shares outstanding as of December 31, 2021	5	4
Additional paid-in capital	218,161	211,263
Common stock in treasury, at cost; 100,152 shares as of June 30, 2022, and December 31, 2021	(1,043)	(1,043)
Accumulated deficit	(203,364)	(196,092)
Total stockholders' equity	13,759	14,132
Total liabilities and stockholders' equity	$ 32,017	$ 37,194

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	275,000,000	275,000,000
Common stock, shares issued	46,815,694	38,874,146
Common stock, shares outstanding	46,715,542	38,773,994
Treasury stock, shares	100,152	100,152

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Revenue	$ 41	$ 11,880	$ 73	$ 16,282
Costs of goods sold	0	11,527	0	18,272
Gross profit	41	353	73	(1,990)
Operating expenses:
Research and development	3,250	2,844	6,191	5,894
Selling, general, and administrative	3,556	3,493	6,736	7,781
Total operating expenses	6,806	6,337	12,927	13,675
Loss from operations	(6,765)	(5,984)	(12,854)	(15,665)
Gain upon extinguishment of Payroll Protection Program Loan	0	1,528	0	1,528
Interest, net	(16)	(357)	(33)	(703)
Non-operating income (expenses)	4,296	6	4,783	5
Loss before income taxes	(2,485)	(4,807)	(8,104)	(14,835)
Income taxes	0	0	0	0
Net loss	$ (2,485)	$ (4,807)	$ (8,104)	$ (14,835)
Earnings Per Share, Basic	$ (0.05)	$ (0.13)	$ (0.18)	$ (0.4)
Earnings Per Share, Diluted	$ (0.05)	$ (0.13)	$ (0.18)	$ (0.4)
Weighted Average Number of Shares Outstanding, Basic	46,663,475	37,199,349	44,354,610	37,168,018
Weighted Average Number of Shares Outstanding, Diluted	46,663,475	37,199,349	44,354,610	37,168,018
Anti-dilutive stock options, restricted stock units, performance stock units, and common stock warrants	16,234,030	5,223,327	16,234,030	5,223,327

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDER'S EQUITY - USD ($) $ in Thousands	Total	ATM Facility Member	Share-based Payment Arrangement [Member]	IPO [Member]	Common Stock [Member]	Common Stock [Member] IPO [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member] ATM Facility Member	Additional Paid-In Capital [Member] Share-based Payment Arrangement [Member]	Additional Paid-In Capital [Member] IPO [Member]	Shares in Treasury [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2020	$ 36,875				$ 4		$ 204,807				$ (1,043)	$ (166,893)
Beginning balance, shares at Dec. 31, 2020					37,065,044
Net loss	(14,835)											(14,835)
Stock-based compensation	(371)						(371)
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock units, shares			140,429
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock units, amount			$ 227						$ 227
Ending balance at Jun. 30, 2021	21,896				$ 4		204,663				(1,043)	(181,728)
Ending balance, shares at Jun. 30, 2021					37,205,473
Beginning balance at Mar. 31, 2021	25,605				$ 4		203,565				(1,043)	(176,921)
Beginning balance, shares at Mar. 31, 2021					37,163,187
Net loss	(4,807)											(4,807)
Stock-based compensation	1,079						1,079
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock units, shares			42,286
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock units, amount			$ 19						$ 19
Ending balance at Jun. 30, 2021	21,896				$ 4		204,663				(1,043)	(181,728)
Ending balance, shares at Jun. 30, 2021					37,205,473
Beginning balance at Dec. 31, 2021	14,132				$ 4		211,263				(1,043)	(196,092)
Beginning balance, shares at Dec. 31, 2021					38,773,994
Net loss	(8,104)											(8,104)
Stock-based compensation	1,855						1,855
Issuance of common stock		$ (7)		$ 5,051		$ 1		$ (7)		$ 5,050
Issuance of common stock, shares				3,880,000
Issuance of common stock upon exercise of pre-funded warrants				3,880,000
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock units, shares			181,548
Cumulative Effect Of Adoption Of Lease Accounting Standard	832											832
Ending balance at Jun. 30, 2022	13,759				$ 5		218,161				(1,043)	(203,364)
Ending balance, shares at Jun. 30, 2022					46,715,542
Beginning balance at Mar. 31, 2022	14,921				$ 5		216,838				(1,043)	(200,879)
Beginning balance, shares at Mar. 31, 2022					42,741,763
Net loss	(2,485)											(2,485)
Stock-based compensation	1,323						1,323
Issuance of common stock				$ 0		$ 0				$ 0
Issuance of common stock, shares				3,880,000
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock units, shares					93,779
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock units, amount		$ 0						$ 0
Ending balance at Jun. 30, 2022	$ 13,759				$ 5		$ 218,161				$ (1,043)	$ (203,364)
Ending balance, shares at Jun. 30, 2022					46,715,542

CONSOLIDATED STATEMENTS OF ST_2

CONSOLIDATED STATEMENTS OF STOCKHOLDER'S EQUITY (Parenthetical) $ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($)
Follow-on Public Offering [Member]
Adjustments to Additional Paid In Capital Stock And Warrants Issued Issuance Costs	$ 0.5

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating activities
Net loss	$ (8,104)	$ (14,835)
Adjustments to reconcile net loss to net cash used by operating activities:
Gain upon extinguishment of Payroll Protection Program Loan	0	(1,528)
Depreciation and amortization	763	1,180
Stock-based compensation	1,855	(371)
Unrealized (gain) loss on mark-to-market of common stock warrants	(4,723)
Changes in operating assets and liabilities:
Accounts receivable		893
Due to/from related parties	(71)	(638)
Inventory		(1,085)
Prepaid expenses and other current assets	5	3,301
Accounts payable	(114)	1,254
Accrued expenses	(87)	(555)
Accrued compensation	(250)	143
Other	(550)	992
Net cash used by operating activities	(11,276)	(11,249)
Investing activities
Proceeds from sales of short-term investments		11,698
Purchases of land, buildings, and equipment	(1,289)	(307)
Net cash (used by) provided by investing activities	(1,289)	11,391
Financing activities
Proceeds from the issuance of common stock and pre-funded warrants	11,209
Costs incurred related to the issuance of common stock, pre-funded warrants, and common warrants	(961)
Repayments of financing lease obligations	(190)	(178)
Proceeds from the exercise of stock options	0	227
Net cash provided by financing activities	10,058	49
Net (decrease) increase in cash, cash equivalents, and restricted cash	(2,507)	191
Cash, cash equivalents and restricted cash - beginning of period	14,421	18,289
Cash, cash equivalents and restricted cash - end of period	$ 11,914	$ 18,480

Basis of Presentation & Summary

Basis of Presentation & Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation & Summary of Significant Accounting Policies	1. BASIS OF PRESENTATION & SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The unaudited consolidated financial statements of Calyxt, Inc. (Calyxt or the Company) have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP or GAAP) for interim financial information and with the rules and regulations of the Securities and Exchange Commission (SEC) applicable to interim financial statements. In the Company’s opinion, the accompanying consolidated financial statements reflect all adjustments necessary for a fair presentation of its statements of financial position, results of operations, and cash flows for the periods presented but they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Except as otherwise disclosed herein, these adjustments consist of normal recurring items. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole or any other interim period. The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the consolidated financial statements and during the reporting period. Actual results could materially differ from these estimates. Certain prior year amounts have been reclassified to conform to the current year presentation. For further information, refer to the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K 10-Q 10-K Net Loss Per Share Due to the Company’s net loss position for the three and six months ended June 30, 2022, and June 30, 2021, all of its outstanding stock options, restricted stock units (RSUs), performance stock units (PSUs), and warrants to purchase common stock (Common Warrants) are considered anti-dilutive and excluded from the calculation of net loss per share. Accordingly, the treasury method was not used in determining the number of anti-dilutive stock options, RSUs, PSUs, or Common Warrants. Warrants The Company issued pre-funded (Pre-Funded follow-on Follow-On The Company also issued Common Warrants in the Follow-On The Common Warrants are reported at fair value with changes in fair value reported in earnings. The Company reports the changes in fair value of the Common Warrants in non-operating Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases No. 2018-10, 2018-11, Leases (Topic right-of-use The Company adopted the Standard as of January 1, 2022, using the transition method which does not require revisions to comparative periods. The Company elected to implement the transition package of practical expedients permitted within the Standard, which among other things, allows it to carryforward the historical lease classification. In addition, the Company elected the hindsight practical expedient to determine the lease term for existing leases and it also made an accounting policy election to not record leases with an initial term of 12 months or less on its consolidated balance sheet. The Company’s adoption of the Standard required it to remove the previously reported amounts for land, buildings, and equipment associated with its headquarters and laboratory facility lease as well as the associated liability. The Company assessed the elements of its lease agreement and upon adoption, recorded an operating lease associated with the sale leaseback of land component of the lease, and a second operating lease associated with the building component of the lease. The Company recorded operating lease assets and liabilities of $14.1 million within its consolidated balance sheet as of January 1, 2022. The Standard had no impact on the Company’s consolidated statements of operations or cash flows. The $0.8 million cumulative effect of the adoption of the Standard was recorded to stockholders’ equity. See Note 8 for further information regarding the Company’s leases. In June 2016, the FASB issued ASU No. 2016-13, 2016-13). 2016-13

Going Concern

Going Concern	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	2. GOING CONCERN The Company has incurred losses since its inception. The Company’s net loss was million of cash for operating activities for the six months ended June 30, 2022. The Company’s primary sources of liquidity are its cash and cash equivalents, with additional liquidity accessible, subject to market conditions and other factors, including limitations that may apply to the Company under applicable SEC and Nasdaq Global Market (Nasdaq) regulations, from the capital markets, including under the Open Market Sale Agreement SM As of June 30, 2022, the Company had $11.9 million of cash, cash equivalents, and restricted cash. The Company’s restricted cash is associated with its equipment financing leases and was $0.6 million as of June 30, 2022, with $0.5 million scheduled to be returned in December 2022. Current liabilities were $4.5 million as of June 30, 2022. On February 23, 2022, the Company issued 3,880,000 shares of its common stock, Pre-Funded Follow-On The Company has incurred losses since its inception and anticipates that it will continue to generate losses for the next several years. Over the longer term and until the Company can generate cash flows sufficient to support its operating capital requirements, it expects to finance a portion of future cash needs through (i) cash on hand, (ii) commercialization activities, which may result in various types of revenue streams from (a) future product development agreements and technology licenses, including upfront and milestone payments, annual license fees, and royalties; and (b) product sales from its proprietary BioFactory production system; (iii) government or other third-party funding, which the Company expects to be more readily available if Cellectis were to own less than 50 percent of the Company’s common stock, (iv) public or private equity or debt financings, or (v) a combination of the foregoing. However, additional capital may not be available on reasonable terms, if at all. For example, based on the Company’s public float, as of the date of the filing of its Annual Report on Form 10-K, S-3, it may not sell more than the equivalent of one-third The Company’s ability to continue as a going concern will depend on its ability to obtain additional public or private equity or debt financing, obtain government or private grants and other similar types of funding, attain further operating efficiencies, reduce or contain expenditures, and, ultimately, to generate revenue. The Company believes that its cash, cash equivalents, and restricted cash as of June 30, 2022, considering its plan to continue to invest in the growth and scaling of its BioFactory production system and related capabilities , the $ million of net proceeds from the Follow-On Offering, and considering additional efforts in reassessing its discretionary spending, is sufficient to fund its operations into early . The Company’s management has concluded there is substantial doubt regarding its ability to continue as a going concern because it anticipates that it will need to raise additional capital to support this business plan for a period of months or more from the date of this filing. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. If the Company is unable to raise additional capital in a sufficient amount or on acceptable terms, management may be required to implement various cost reduction and other cash-focused measures to manage liquidity and the Company may have to significantly delay, scale back, or cease operations, in part or in full. If the Company raises additional funds through the issuance of additional debt or equity securities, it could result in dilution to its existing stockholders and increased fixed payment obligations, and these securities may have rights senior to those of the Company’s shares of common stock. Any of these events could significantly harm the Company’s business, financial condition, and prospects.

Financial Instruments Measured

Financial Instruments Measured at Fair Value and Concentrations of Credit Risk	6 Months Ended
	Jun. 30, 2022
Text Block [Abstract]
Financial Instruments Measured at Fair Value and Concentrations of Credit Risk	3. FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE AND CONCENTRATIONS OF CREDIT RISK Financial Instruments Measured at Fair Value and Financial Statement Presentation Financial instruments including cash and cash equivalents, restricted cash, accounts payable, and all other current liabilities have carrying values that approximate fair value. The Company measures common stock warrants on a quarterly basis. The accounting guidance establishes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as of the measurement date as follows: Level 1: Fair values are based on unadjusted quoted prices in active trading markets for identical assets and liabilities. Level 2: Fair values are based on observable quoted prices other than those in Level 1, such as quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets. Level 3: Fair values are based on at least one significant unobservable input for the asset or liability. Fair Value Measurements and Financial Statement Presentation The fair values of the Company’s financial instruments measured at fair value and their respective levels in the fair value hierarchy as of June 30, 2022, were as follows: June 30, 2022 June 30, 2022 Fair Values of Assets Fair Values of Liabilities In Thousands Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Other items reported at fair value: Common stock warrants $ — $ — $ — $ — $ — $ — $ 688 $ 688 Total $ — $ — $ — $ — $ — $ — $ 688 $ 688 The Company estimates the fair value of each Common Warrant as of the date of issuance and at the end of every fiscal period using a Black-Scholes option pricing model, which requires it to make predictive assumptions regarding future stock price volatility and dividend yield. The Company estimates the risk-free interest rate based on the United States Treasury zero-coupon The estimated fair values of the Common Warrants, and the assumptions used for the Black-Scholes option pricing model were as follows: As of June 30, Estimated fair value of Common Warrants $ 0.09 Assumptions: Risk-free interest rate 3.0 % Expected volatility 85.0 % Expected term to liquidation (in years) 5.2 As of June 30, 2022, the Company had no other financial instruments measured at fair value. The non-current portion of the Company’s financing lease obligations are also considered a financial instrument, which the Company measures at fair value for disclosure purposes. It is a Level 2 liability and had a nominal fair value as of June 30, 2022, and a fair value of $14.5 million a Foreign Exchange Risk Foreign currency fluctuations affect the Company’s foreign currency cash flows related primarily to payments to Cellectis. The Company’s principal foreign currency exposure is to the euro. The Company does not hedge these exposures, and it does not believe that the current level of foreign currency risk is significant to its operations. Concentrations of Credit Risk The Company invests its cash, cash equivalents, and restricted cash in highly liquid securities and investment funds. The Company diversifies the risk associated with investing in securities by allocating its investments to a diverse portfolio of short-dated, high investment-grade securities, which it classifies as short-term investments that are recorded at fair value in its consolidated financial statements. The Company maintains the credit risk in this portfolio in accordance with its internal policies and if necessary, makes changes to investments to minimize credit risk. The Company has not experienced any counterparty credit losses. As of June 30, 2022, the Company did not hold any short-term investments.

Related-Party Transactions

Related-Party Transactions	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Related-Party Transactions	4. RELATED-PARTY TRANSACTIONS The Company is party to several agreements that govern its relationship with Cellectis, some of which require the Company to make payments to Cellectis. Pursuant to the Company’s management services agreement with Cellectis, it incurred no management fee expenses for the three and six months ended June 30, 2022, and it incurred nominal management fee expenses for the three and six months ended June 30, 2021. Cellectis has also guaranteed the lease agreement for the Company’s headquarters. Cellectis’ guarantee of the Company’s obligations under the lease will terminate at the end of the second consecutive calendar year in which the Company’s tangible net worth exceeds $300 million. At a point when Cellectis owns 50 percent or less of the Company’s outstanding common stock, the Company has agreed to indemnify Cellectis for any obligations incurred by Cellectis under its guaranty of the obligations under the lease. TALEN ® ® ®

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2022
Federal Home Loan Banks [Abstract]
Stockholders' Equity	5. STOCKHOLDERS’ EQUITY Follow-On On February 23, 2022, the Company completed the Follow-On Pre-Funded Pre-Funded Each Pre-Funded Warrant entitled the holder to purchase one share of the Company’s common stock at an exercise price of per share. The Pre-Funded paid-in Pre-Funded Common Stock Warrants Each Common Warrant entitles the holder to purchase one share of common stock at an exercise price of $1.41 per share. The Common Warrants will be exercisable beginning August 23, 2022 and expire on August 23, 2027. The Common Warrants are recorded as a liability in the Company’s consolidated balance sheet. Per the terms of the Common Warrants, a holder of an outstanding warrant is not entitled to exercise any portion of such warrant if, upon exercise of such portion of the warrant, the holder’s ownership of the Company’s common stock (together with its affiliates) or the combined voting power of the Company’s securities beneficially owned by such holder (together with its affiliates) would exceed the 4.99 percent after giving effect to the exercise. Warrant transactions for the six months ended June 30, 2022, are as follows: Number of Pre-Funded Warrants Weighted Average Number of Warrants Weighted Outstanding as of December 31, 2021: Issued 3,880,000 $ 0.0001 7,760,000 $ 1.41 Forfeited/canceled — — — — Exercised 3,880,000 $ 0.0001 — Outstanding as of June 30, 2022: — — 7,760,000 $ 1.41 Exercisable as of June 30, 2022: — — — — ATM Facility On September 21, 2021, the Company entered into an ATM Facility with Jefferies LLC who is acting as sole selling agent. Under the terms of the ATM Facility, the Company may, from time-to-time,

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2022
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	6. STOCK-BASED COMPENSATION The Company uses broad-based stock plans to attract and retain highly qualified officers and employees and to help ensure that management’s interests are aligned with those of its shareholders. The Company has also granted equity-based awards to directors, nonemployees, and certain employees of Cellectis. In December 2014, the Company adopted the Calyxt, Inc. Equity Incentive Plan (2014 Plan), which allowed for the grant of stock options, and in June 2017, it adopted the 2017 Omnibus Plan (2017 Plan), which allowed for the grant of stock options, restricted stock units, performance stock units and other types of equity awards. In July 2021, the Company also adopted the Calyxt, Inc. Employee Inducement Incentive Plan (the Inducement Plan), from which PSUs were granted to Michael A. Carr. On February 19, 2021, James Blome ceased serving as the Company’s Chief Executive Officer. In the six-month period ended June 30, 2021, the Company recorded a benefit to earnings from a $2.5 million recapture of non-cash As of June 30, 2022, 2,621,614 shares were registered and available for grant under effective registration statements, while 2,961,677 shares were available for grant in the form of stock options, restricted stock, restricted stock units, and performance stock units under the 2017 Plan. Stock-based awards currently outstanding also include awards granted under the 2014 Plan and the Inducement Plan. No further awards will be granted under either the 2014 Plan or the Inducement Plan. Stock Options The estimated fair values of stock options granted, and the assumptions used for the Black-Scholes option pricing model were as follows: Six Months Ended June 30, 2022 2021 Estimated fair values of stock options granted $ 0.86 $ 4.54 Assumptions: Risk-free interest rate 1.9% - 3.5 % 0.6% - 1.1 % Expected volatility 89.7% - 92.8 % 80.1% - 82.0 % Expected term (in years) 5.50 - 6.89 5.5 - 6.5 The Company estimates the fair value of each stock option on the grant date, or other measurement date if applicable, using a Black-Scholes option pricing model, which requires it to make predictive assumptions regarding employee exercise behavior, future stock price volatility, and dividend yield. The Company estimates the risk-free interest rate based on the United States Treasury zero-coupon Option strike prices are set at 100 percent or more of the closing share price on the date of grant and generally vest over three Information on stock option activity is as follows: Options Exercisable Weighted- Exercise Price Per Share Options Outstanding Weighted- Average Exercise Price Per Share Balance as of December 31, 2021 2,789,110 $ 10.23 4,658,405 $ 9.47 Granted 1,609,000 1.12 Exercised — — Forfeited or expired (329,417 ) 7.82 Balance as of June 30, 2022 3,018,231 $ 10.20 5,937,988 $ 7.30 Stock-based compensation expense related to stock option awards is as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2022 2021 2022 2021 Stock-based compensation expense $ 709 $ 800 $ 890 $ 405 As of June 30, 2022, options outstanding and exercisable had no aggregate intrinsic value and the weighted average remaining contractual term was 5.3 years as of that date. Net cash proceeds from the exercise of stock options less shares used for minimum withholding taxes and the intrinsic value of options exercised were as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2022 2021 2022 2021 Net cash proceeds $ — $ 19 $ — $ 227 Intrinsic value of options exercised $ — $ 13 $ — $ 344 As of June 30, 2022, unrecognized compensation expense related to non-vested Restricted Stock Units The Company grants restricted stock units which generally vest over three Number of Restricted Stock Units Outstanding Weighted- Average Grant Date Fair Value Unvested balance as of December 31, 2021 571,303 $ 6.15 Granted 1,077,600 1.26 Vested (181,248 ) 6.38 Forfeited (61,613 ) 5.55 Unvested balance as of June 30, 2022 1,406,042 $ 2.40 The total grant-date fair value of restricted stock unit awards that vested is as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2022 2021 2022 2021 Grant-date fair value $ 539 $ 390 $ 1,156 $ 641 Stock-based compensation expense related to restricted stock units is as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2022 2021 2022 2021 Stock-based compensation expense $ 453 $ 228 $ 658 $ (521 ) As of June 30, 2022, unrecognized compensation expense related to restricted stock units was $2.0 million. This expense will be recognized over 27 months on average. The Company accounts for stock-based compensation awards granted to employees of Cellectis as deemed dividends. The Company recorded deemed dividends as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2022 2021 2022 2021 Deemed dividends from grants to Cellectis employees $ 27 $ 107 $ 64 $ 28 Performance Stock Units In June 2022, PSU grants made to two executive officers in 2019 were forfeited because the underlying performance criteria were not met. These PSUs contained a market condition and had a five-year service period. The Company will continue to expense these PSUs over the remaining service period. In March 2022, the Company granted 530,000 PSUs under the 2017 In July 2021, the Company granted 600,000 PSUs under the Inducement Plan to Mr. Carr. The PSUs will vest if the Company’s stock remains above three specified price levels for thirty calendar days over the three-year performance period. The PSUs will be settled in unrestricted shares of the Company’s common stock on the vesting date. PSU activity for the six months ended June 30, 2022, is as follows: Number of PSUs Outstanding as of December 31, 2021: Issued 745,000 530,000 Forfeited/canceled (145,000 ) Exercised — Outstanding as of June 30, 2022: 1,130,000 Stock-based compensation expense related to PSUs is as follows: Three Months Ended Six Months Ended In Thousands 2022 2021 2022 2021 Stock-based compensation expense $ 161 $ 51 $ 307 $ (255 ) As of June 30, 2022, unrecognized compensation expense related to PSUs was $1.3 million. This expense will be recognized over 25 months on average.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	7. INCOME TAXES The Company provides for a valuation allowance when it is more likely than not that it will not realize a portion of the deferred tax assets. The Company has established a full valuation allowance for deferred tax assets due to the uncertainty that enough taxable income will be generated in the taxing jurisdiction to utilize the assets. Therefore, the Company has not reflected any benefit of such deferred tax assets in the accompanying consolidated financial statements. As of June 30, 2022, there were no material changes to what the Company disclosed regarding tax uncertainties or penalties as of December 31, 2021.

Leases, Commitments, and Contin

Leases, Commitments, and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Leases, Commitments, and Contingencies	8. LEASES, COMMITMENTS, AND CONTINGENCIES Leases In February 2016, the FASB issued ASU No. 2016-02, Leases No. 2018-10, 2018-11, Leases (Topic The Company’s leases are summarized as follows: • A lease for its headquarters and laboratory facilities in Roseville, MN which encompasses approximately 38,000 square feet. The original lease term was 20 years, and the Company holds four 5-year renewal options. Historically, this lease was considered a failed sale leaseback based on the nature of the transactions and was reported as a financing-type lease. • An equipment financing arrangement that is considered a financing-type lease. This arrangement has a term of four years for each draw. The Company was required to deposit cash into a restricted account in an amount equal to the future rent payments required by the lease. As of June 30, 2022, restricted cash totaled $0.6 million. The Company has the option to request the return of excess collateral annually in December, and the amount the Company expects to receive is reflected as a current asset. • A small number of short-term and immaterial leases for office equipment. The Company’s adoption of the Standard required it to remove its existing land, buildings, and equipment associated with its headquarters lease as well as the associated liability. The Company assessed the elements of its lease agreement and upon adoption, recorded an operating lease associated with the sale leaseback of land underlying the headquarter facility, and a second operating lease associated with the building. The cumulative effect of the adoption of the Standard was recorded to stockholders’ equity. The impact of adoption on the Company’s December 31, 2021, consolidated balance sheet was as follows: As Reported Adoption of As Adjusted Assets Land, buildings, and equipment $ 21,731 $ (16,543 ) $ 5,188 Operating lease right-of-use assets — 14,090 14,090 $ 21,731 $ (2,453 ) $ 19,278 Liabilities and stockholders’ equity Current portion of financing lease obligations $ 370 $ (4 ) $ 366 Other current liabilities 191 276 467 Financing lease obligations 17,506 (17,371 ) 135 Operating lease obligations — 13,814 13,814 Accumulated deficit (196,092 ) 832 (195,260 ) $ (178,025 ) $ (2,453 ) $ (180,478 ) The Company records its operating lease liabilities at the present value of the future lease payments over the lease term. If the lease term includes options to extend or terminate the lease, those elements are included in the determination of lease term when it is reasonably certain that the option will be exercised. The rate used to determine the present value of future lease payments is the rate stated in the lease agreement, or if not stated, the Company’s incremental borrowing rate is used, up to an effective rate that enables the lease liability to amortize to zero over the lease term. Rent expense for operating leases is recorded in selling, general, and administrative (SG&A) expense in the consolidated statements of operations and in operating cash flows in the consolidated statements of cash flows. The Company also records operating lease right-of-use assets at an initial amount equal to the operating lease liability. Those right-of-use assets are amortized to lease expense within SG&A over the lease term using the effective interest method to ensure the right-of-use asset amortizes to zero concurrent with the associated liability, and the right-of-use asset amortization expense is also reported in operating cash flows in the consolidated statements of cash flows. The Company records its financing lease liabilities at the present value of the future lease payments over the lease term. If the lease term includes options to extend or terminate the lease, those elements are included in the determination of lease term when it is reasonably certain that the option will be exercised. The rate used to determine the present value of future lease payments is the rate stated in the lease agreement, or if not stated, the Company’s incremental borrowing rate is used, up to an effective rate that enables the lease liability to amortize to zero over the lease term. Expense associated with financing leases is recorded in interest, net in the consolidated statements of operations and in operating cash flows in the consolidated statements of cash flows. The Company is obligated under non-cancellable As of June 30, 2022 Remaining Right-of-Use In Thousands Term (years) Asset Roseville, MN lease 15.8 $ 13,852 Total $ 13,852 The Roseville, MN lease includes four options to each extend the lease for 5 years. These options to extend the lease are not recognized as part of the right-of-use The components of lease expense were as follows: In Thousands Three Months Ended Six Months Ended Finance lease costs $ 7 $ 16 Operating lease costs 394 793 Variable lease costs 227 458 Total $ 628 $ 1,267 Operating lease cost for short-term leases was not material for the six months ended June 30, 2022. Other information related to leases was as follows: In Thousands except for lease term and discount rate As of and for Six Months Ended Operating Financing Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows $ 135 $ — Financing cash flows $ — $ 190 Weighted average remaining lease term (years) 15.8 0.5 Weighted average discount rate 7.9 % 8.1 % As of June 30, 2022, future minimum payments under operating and finance leases were as follows: In Thousands Operating Financing Total Remainder of 2022 $ 689 $ 258 $ 947 2023 1,446 38 1,484 2024 1,480 — 1,480 2025 1,479 — 1,479 2026 1,479 — 1,479 2027 1,479 — 1,479 Thereafter 16,991 — 16,991 25,043 296 25,339 Less: imputed interest (11,088 ) (13 ) (11,101 ) Total $ 13,955 $ 283 $ 14,238 Litigation and Claims The Company is not currently a party to any material pending legal proceeding.

Supplemental Information

Supplemental Information	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Supplemental Information	9. SUPPLEMENTAL INFORMATION Certain statement of operations amounts are as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2022 2021 2022 2021 Stock-based compensation expense: Research and development $ 380 $ 417 $ 410 $ 809 Selling, general, and administrative 943 662 1,445 (1,180 ) Total $ 1,323 $ 1,079 $ 1,855 $ (371 ) Three Months Ended June 30, Six Months Ended June 30, In Thousands 2022 2021 2022 2021 Interest, net: Interest expense $ (6 ) $ (359 ) $ (16 ) $ (719 ) Interest income 12 2 13 16 Common stock warrants - financing costs amortization (22 ) — (30 ) — Total $ (16 ) $ (357 ) $ (33 ) $ (703 ) Certain balance sheet amounts are as follows: In Thousands As of June 30, As of December 31, Cash, cash equivalents, and restricted cash: Cash and cash equivalents $ 11,316 $ 13,823 Restricted cash 545 499 Non-current 53 99 Total $ 11,914 $ 14,421 Supplemental statement of cash flows information is as follows: As of June 30, In Thousands 2022 2021 Interest paid $ 14 $ 716 Non-cash As of June 30, In Thousands 2022 2021 Receivable from Jefferies for shares issued under ATM facility $ (260 ) $ — Non-cash $ (618 ) $ — Unpaid stock offering costs included in stockholders’ equity $ 1 $ — Cumulative effect of adoption of lease accounting standard on stockholders’ equity $ 832 $ — Establishment of operating lease right-of-use $ 14,090 $ —

Basis of Presentation & Summa_2

Basis of Presentation & Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Warrants	Warrants The Company issued pre-funded (Pre-Funded follow-on Follow-On The Company also issued Common Warrants in the Follow-On The Common Warrants are reported at fair value with changes in fair value reported in earnings. The Company reports the changes in fair value of the Common Warrants in non-operating
Net Loss Per Share	Net Loss Per Share Due to the Company’s net loss position for the three and six months ended June 30, 2022, and June 30, 2021, all of its outstanding stock options, restricted stock units (RSUs), performance stock units (PSUs), and warrants to purchase common stock (Common Warrants) are considered anti-dilutive and excluded from the calculation of net loss per share. Accordingly, the treasury method was not used in determining the number of anti-dilutive stock options, RSUs, PSUs, or Common Warrants.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases No. 2018-10, 2018-11, Leases (Topic right-of-use The Company adopted the Standard as of January 1, 2022, using the transition method which does not require revisions to comparative periods. The Company elected to implement the transition package of practical expedients permitted within the Standard, which among other things, allows it to carryforward the historical lease classification. In addition, the Company elected the hindsight practical expedient to determine the lease term for existing leases and it also made an accounting policy election to not record leases with an initial term of 12 months or less on its consolidated balance sheet. The Company’s adoption of the Standard required it to remove the previously reported amounts for land, buildings, and equipment associated with its headquarters and laboratory facility lease as well as the associated liability. The Company assessed the elements of its lease agreement and upon adoption, recorded an operating lease associated with the sale leaseback of land component of the lease, and a second operating lease associated with the building component of the lease. The Company recorded operating lease assets and liabilities of $14.1 million within its consolidated balance sheet as of January 1, 2022. The Standard had no impact on the Company’s consolidated statements of operations or cash flows. The $0.8 million cumulative effect of the adoption of the Standard was recorded to stockholders’ equity. See Note 8 for further information regarding the Company’s leases. In June 2016, the FASB issued ASU No. 2016-13, 2016-13). 2016-13

Financial Instruments Measure_2

Financial Instruments Measured at Fair Value and Concentrations of Credit Risk (Tables)	6 Months Ended
	Jun. 30, 2022
Text Block [Abstract]
Summary of Fair Value Measurements and Financial Statement Presentation	The fair values of the Company’s financial instruments measured at fair value and their respective levels in the fair value hierarchy as of June 30, 2022, were as follows: June 30, 2022 June 30, 2022 Fair Values of Assets Fair Values of Liabilities In Thousands Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Other items reported at fair value: Common stock warrants $ — $ — $ — $ — $ — $ — $ 688 $ 688 Total $ — $ — $ — $ — $ — $ — $ 688 $ 688
Summary of Fair Value of the Common Warrants	The estimated fair values of the Common Warrants, and the assumptions used for the Black-Scholes option pricing model were as follows: As of June 30, Estimated fair value of Common Warrants $ 0.09 Assumptions: Risk-free interest rate 3.0 % Expected volatility 85.0 % Expected term to liquidation (in years) 5.2

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2022
Text Block [Abstract]
Disclosure of Warrants Transactions	Warrant transactions for the six months ended June 30, 2022, are as follows: Number of Pre-Funded Warrants Weighted Average Number of Warrants Weighted Outstanding as of December 31, 2021: Issued 3,880,000 $ 0.0001 7,760,000 $ 1.41 Forfeited/canceled — — — — Exercised 3,880,000 $ 0.0001 — Outstanding as of June 30, 2022: — — 7,760,000 $ 1.41 Exercisable as of June 30, 2022: — — — —

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Fair Values of Stock Options Granted and Assumptions used in Black-Scholes Model	The estimated fair values of stock options granted, and the assumptions used for the Black-Scholes option pricing model were as follows: Six Months Ended June 30, 2022 2021 Estimated fair values of stock options granted $ 0.86 $ 4.54 Assumptions: Risk-free interest rate 1.9% - 3.5 % 0.6% - 1.1 % Expected volatility 89.7% - 92.8 % 80.1% - 82.0 % Expected term (in years) 5.50 - 6.89 5.5 - 6.5
Summary of Stock Option Activity	Information on stock option activity is as follows: Options Exercisable Weighted- Exercise Price Per Share Options Outstanding Weighted- Average Exercise Price Per Share Balance as of December 31, 2021 2,789,110 $ 10.23 4,658,405 $ 9.47 Granted 1,609,000 1.12 Exercised — — Forfeited or expired (329,417 ) 7.82 Balance as of June 30, 2022 3,018,231 $ 10.20 5,937,988 $ 7.30
Summary of Stock-based Compensation Expense	Stock-based compensation expense related to PSUs is as follows: Three Months Ended Six Months Ended In Thousands 2022 2021 2022 2021 Stock-based compensation expense $ 161 $ 51 $ 307 $ (255 )
Schedule of Net Cash Proceeds from Exercise of Stock Options Less Shares Used for Minimum Withholding Taxes and Intrinsic Value of Options Exercised	Net cash proceeds from the exercise of stock options less shares used for minimum withholding taxes and the intrinsic value of options exercised were as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2022 2021 2022 2021 Net cash proceeds $ — $ 19 $ — $ 227 Intrinsic value of options exercised $ — $ 13 $ — $ 344
Summary of Activity of Restricted Stock Units	Information on restricted stock unit activity is as follows: Number of Restricted Stock Units Outstanding Weighted- Average Grant Date Fair Value Unvested balance as of December 31, 2021 571,303 $ 6.15 Granted 1,077,600 1.26 Vested (181,248 ) 6.38 Forfeited (61,613 ) 5.55 Unvested balance as of June 30, 2022 1,406,042 $ 2.40
Summary of Grant Date Fair Value of Restricted Stock Unit Awards Vested	The total grant-date fair value of restricted stock unit awards that vested is as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2022 2021 2022 2021 Grant-date fair value $ 539 $ 390 $ 1,156 $ 641
Summary of Stock-Based Compensation Granted As Deemed Dividends	The Company accounts for stock-based compensation awards granted to employees of Cellectis as deemed dividends. The Company recorded deemed dividends as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2022 2021 2022 2021 Deemed dividends from grants to Cellectis employees $ 27 $ 107 $ 64 $ 28
Share-based Payment Arrangement, Performance Shares, Outstanding Activity	PSU activity for the six months ended June 30, 2022, is as follows: Number of PSUs Outstanding as of December 31, 2021: Issued 745,000 530,000 Forfeited/canceled (145,000 ) Exercised — Outstanding as of June 30, 2022: 1,130,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Stock-based Compensation Expense	Stock-based compensation expense related to stock option awards is as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2022 2021 2022 2021 Stock-based compensation expense $ 709 $ 800 $ 890 $ 405
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Stock-based Compensation Expense	Stock-based compensation expense related to restricted stock units is as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2022 2021 2022 2021 Stock-based compensation expense $ 453 $ 228 $ 658 $ (521 )

Leases, Commitments, and Cont_2

Leases, Commitments, and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2022
Lease, Cost [Abstract]
Schedule Of Impact Of Adoption Of The Standard On Consolidated Balance Sheet	The impact of adoption on the Company’s December 31, 2021, consolidated balance sheet was as follows: As Reported Adoption of As Adjusted Assets Land, buildings, and equipment $ 21,731 $ (16,543 ) $ 5,188 Operating lease right-of-use assets — 14,090 14,090 $ 21,731 $ (2,453 ) $ 19,278 Liabilities and stockholders’ equity Current portion of financing lease obligations $ 370 $ (4 ) $ 366 Other current liabilities 191 276 467 Financing lease obligations 17,506 (17,371 ) 135 Operating lease obligations — 13,814 13,814 Accumulated deficit (196,092 ) 832 (195,260 ) $ (178,025 ) $ (2,453 ) $ (180,478 )
Summary of Non Cancellable Operating Leases	The Company is obligated under non-cancellable As of June 30, 2022 Remaining Right-of-Use In Thousands Term (years) Asset Roseville, MN lease 15.8 $ 13,852 Total $ 13,852
Summary of Lease Cost	The components of lease expense were as follows: In Thousands Three Months Ended Six Months Ended Finance lease costs $ 7 $ 16 Operating lease costs 394 793 Variable lease costs 227 458 Total $ 628 $ 1,267
Summary of Other Information Related to Leases	Other information related to leases was as follows: In Thousands except for lease term and discount rate As of and for Six Months Ended Operating Financing Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows $ 135 $ — Financing cash flows $ — $ 190 Weighted average remaining lease term (years) 15.8 0.5 Weighted average discount rate 7.9 % 8.1 %
Summary of Future Minimum Rental Payments	As of June 30, 2022, future minimum payments under operating and finance leases were as follows: In Thousands Operating Financing Total Remainder of 2022 $ 689 $ 258 $ 947 2023 1,446 38 1,484 2024 1,480 — 1,480 2025 1,479 — 1,479 2026 1,479 — 1,479 2027 1,479 — 1,479 Thereafter 16,991 — 16,991 25,043 296 25,339 Less: imputed interest (11,088 ) (13 ) (11,101 ) Total $ 13,955 $ 283 $ 14,238

Supplemental Information (Table

Supplemental Information (Tables)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Certain Statements of Operations Amounts	Certain statement of operations amounts are as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2022 2021 2022 2021 Stock-based compensation expense: Research and development $ 380 $ 417 $ 410 $ 809 Selling, general, and administrative 943 662 1,445 (1,180 ) Total $ 1,323 $ 1,079 $ 1,855 $ (371 ) Three Months Ended June 30, Six Months Ended June 30, In Thousands 2022 2021 2022 2021 Interest, net: Interest expense $ (6 ) $ (359 ) $ (16 ) $ (719 ) Interest income 12 2 13 16 Common stock warrants - financing costs amortization (22 ) — (30 ) — Total $ (16 ) $ (357 ) $ (33 ) $ (703 )
Schedule of Certain Balance Sheet Amounts	Certain balance sheet amounts are as follows: In Thousands As of June 30, As of December 31, Cash, cash equivalents, and restricted cash: Cash and cash equivalents $ 11,316 $ 13,823 Restricted cash 545 499 Non-current 53 99 Total $ 11,914 $ 14,421
Schedule of Statements of Certain Statements of Cash Flows Amounts	Supplemental statement of cash flows information is as follows: As of June 30, In Thousands 2022 2021 Interest paid $ 14 $ 716 Non-cash As of June 30, In Thousands 2022 2021 Receivable from Jefferies for shares issued under ATM facility $ (260 ) $ — Non-cash $ (618 ) $ — Unpaid stock offering costs included in stockholders’ equity $ 1 $ — Cumulative effect of adoption of lease accounting standard on stockholders’ equity $ 832 $ — Establishment of operating lease right-of-use $ 14,090 $ —

Basis of Presentation & Summa_3

Basis of Presentation & Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jan. 01, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Operating lease right-of-use assets	$ 13,855		$ 0
Operating lease obligations	13,652		$ 0
Accounting Standards Update 2016-02 [Member]
Property, Plant and Equipment [Line Items]
Operating lease right-of-use assets		$ 14,100
Operating lease obligations		$ 14,100
Stockholders equity cumulative effect of adoption of lease accounting standard.	$ 800
Follow On Offering [Member]
Property, Plant and Equipment [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.41
Date from which Warrants or Rights Exercisable	Aug. 23, 2027

Going Concern - Additional Info

Going Concern - Additional Information (Details) - USD ($)		3 Months Ended		6 Months Ended
	Feb. 23, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net loss		$ 2,485,000	$ 4,807,000	$ 8,104,000	$ 14,835,000
Net cash used by operating activities				11,276,000	11,249,000
Cash, cash equivalents, and restricted cash		11,914,000	$ 18,480,000	11,914,000	$ 18,480,000		$ 14,421,000	$ 18,289,000
Cash expense for separation-related payments		545,000		545,000		$ 500,000	499,000
Current liabilities		4,501,000		4,501,000			$ 4,854,000
Common stock, issued and sold	3,880,000
Issuance of common stock	$ 10,000,000
After deduction of underwriting discounts and estimated other offering expenses	$ 900,000
Shelf Registration Statement [Member] | ATM Facility [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Minimum public float		75,000,000		$ 75,000,000
Maximum [Member] | Cellectis [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Threshold percentage of ownership in outstanding common stock to enact indemnification agreement				50%
Pre-funded Warrants [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants issued (in shares)	3,880,000
Common Warrants [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants issued (in shares)	7,760,000
Equipment [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Restricted cash		$ 600,000		$ 600,000

Financial Instruments Measure_3

Financial Instruments Measured at Fair Value and Concentrations of Credit Risk - Summary of Fair Value Measurements and Financial Statement Presentation (Detail) $ in Thousands	Jun. 30, 2022 USD ($)
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Liabilities	$ 688
Common Stock Warrants [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Liabilities	688
Level 3 [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Liabilities	688
Level 3 [Member] | Common Stock Warrants [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Liabilities	$ 688

Financial instruments and finan

Financial instruments and financial risk management - Summary of Fair Value of the Common Warrants (Details)	Jun. 30, 2022 yr
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated fair value of Common Warrants	0.09
Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumptions	3
Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumptions	85
Expected term to liquidation (in years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumptions	5.2

Financial Instruments Measure_4

Financial Instruments Measured at Fair Value and Concentrations of Credit Risk - Additional Information (Detail) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair value of financing leases		$ 14.5
Corporate Debt Securities [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Other Financial Instruments	$ 0

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Detail) - Cellectis [Member] $ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($)
Related Party Transaction [Line Items]
Minimum net worth required	$ 300
Maximum [Member]
Related Party Transaction [Line Items]
Threshold percentage of ownership in outstanding common stock to enact indemnification agreement	50%

Stockholders' Equity - Summary

Stockholders' Equity - Summary Of Warrants Transactions (Detail) - $ / shares	6 Months Ended
	Jun. 30, 2022	Feb. 23, 2022
Pre Funded Warrants [Member]
Disclosure of Warrants Transactions [Line Items]
Number of restricted stock units outstanding, Issued	3,880,000
Weighted-average grant date fair value, Issued	$ 0.0001
Number of restricted stock units outstanding, Exercised	3,880,000
Number of restricted stock units outstanding, Unvested ending balance	0
Weighted-average grant date fair value, Unvested ending balance	$ 0
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	0
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0	$ 0.0001
Common Stock Warrants [Member]
Disclosure of Warrants Transactions [Line Items]
Number of restricted stock units outstanding, Issued	7,760,000
Weighted-average grant date fair value, Issued	$ 1.41
Number of restricted stock units outstanding, Unvested ending balance	7,760,000
Weighted-average grant date fair value, Unvested ending balance	$ 1.41
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1.41

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions		6 Months Ended
	Feb. 23, 2022	Jun. 30, 2022
Equity, Class of Treasury Stock [Line Items]
Common stock, issued and sold	3,880,000
Net proceeds from issuance of common stock and exercise of overallotment	$ 10
After deduction of underwriting discounts and estimated other offering expenses	$ 0.9
ATM Facility [Member]
Equity, Class of Treasury Stock [Line Items]
Aggregate common stock offering value		$ 50
Pre-funded Warrants [Member]
Equity, Class of Treasury Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.0001	$ 0
Pre-funded Warrants [Member] | Maximum [Member]
Equity, Class of Treasury Stock [Line Items]
Warrants issued (in shares)	3,880,000
Common Warrants [Member] | Maximum [Member]
Equity, Class of Treasury Stock [Line Items]
Warrants issued (in shares)	7,760,000
Common Stock Warrants [Member]
Equity, Class of Treasury Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.41
Common Stock, Voting Rights	4.99
Common Stock Warrants [Member] | Maximum [Member]
Equity, Class of Treasury Stock [Line Items]
Date from which Warrants or Rights Exercisable	Aug. 23, 2027
Common Stock Warrants [Member] | Minimum [Member]
Equity, Class of Treasury Stock [Line Items]
Date from which Warrants or Rights Exercisable	Aug. 23, 2022
Follow-on Public Offering [Member]
Equity, Class of Treasury Stock [Line Items]
Common stock, issued and sold	3,880,000
Common stock issued price per share	$ 1.41
Net proceeds from issuance of common stock and exercise of overallotment	$ 10
After deduction of underwriting discounts and estimated other offering expenses	$ 0.9
Follow-on Public Offering [Member] | Pre-funded Warrants [Member]
Equity, Class of Treasury Stock [Line Items]
Common stock issued price per share	$ 1.4099
Follow-on Public Offering [Member] | Pre-funded Warrants [Member] | Maximum [Member]
Equity, Class of Treasury Stock [Line Items]
Warrants issued (in shares)	3,880,000
Follow-on Public Offering [Member] | Common Warrants [Member] | Maximum [Member]
Equity, Class of Treasury Stock [Line Items]
Warrants issued (in shares)	7,760,000

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ in Millions	Jun. 30, 2022	Feb. 19, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares registered and available for grant	2,621,614
Mr. Blome [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected benefit to earnings from recapture of non-cash stock compensation expense		$ 2.5
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares registered and available for grant	2,961,677

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Fair Values of Stock Options Granted and Assumptions used in Black-Scholes Model (Detail) - Stock Options [Member] - $ / shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated fair values of stock options granted	$ 0.86	$ 4.54
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.90%	0.60%
Expected volatility	89.70%	80.10%
Expected term (in years)	5 years 6 months	5 years 6 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	3.50%	1.10%
Expected volatility	92.80%	82%
Expected term (in years)	6 years 10 months 20 days	6 years 6 months

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Options - Additional Information (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options priced at fair market value, Percent	100%
Stock option expiration period	10 years
2017 Omnibus Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option, vesting period	3 years
2017 Omnibus Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option, vesting period	6 years
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average remaining contractual term	5 years 3 months 18 days
Aggregate intrinsic value of options outstanding and exercisable	$ 0
Unrecognized stock-based compensation expense related to non-vested stock options	$ 4,500
Unrecognized stock-based compensation expense, expected recognition weighted-average period	25 months

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Stock Option Activity (Detail)	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Share-based Payment Arrangement [Abstract]
Options Exercisable, Beginning Balance | shares	2,789,110
Options Exercisable, Ending Balance | shares	3,018,231
Weighted-Average Exercise Price Per Share, Beginning Balance | $ / shares	$ 10.23
Weighted-Average Exercise Price Per Share, Ending Balance | $ / shares	$ 10.2
Options Outstanding, Beginning Balance | shares	4,658,405
Options Outstanding, Granted | shares	1,609,000
Options Outstanding, Forfeited or expired | shares	(329,417)
Options Outstanding, Ending Balance | shares	5,937,988
Weighted-Average Exercise Price Per Share, Beginning Balance | $ / shares	$ 9.47
Weighted-Average Exercise Price Per Share, Granted | $ / shares	1.12
Weighted-Average Exercise Price Per Share, Forfeited or expired | $ / shares	7.82
Weighted-Average Exercise Price Per Share, Ending Balance | $ / shares	$ 7.3

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Stock-Based Compensation Expense Related to Stock Option Awards (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 1,323	$ 1,079	$ 1,855	$ (371)
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 709	$ 800	$ 890	$ 405

Stock-Based Compensation - Su_4

Stock-Based Compensation - Summary of Net Cash Proceeds from Exercise of Stock Options Less Shares Used for Minimum Withholding Taxes and Intrinsic Value of Options Exercised (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Net cash proceeds	$ 0	$ 19	$ 0	$ 227
Intrinsic value of options exercised	$ 0	$ 13	$ 0	$ 344

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Units - Additional Information (Detail) $ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($)
2017 Omnibus Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
2017 Omnibus Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	6 years
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to restricted stock units	$ 2
Unrecognized stock-based compensation expense, expected recognition weighted-average period	27 months
Restricted Stock Units [Member] | 2017 Omnibus Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Restricted Stock Units [Member] | 2017 Omnibus Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years

Stock-Based Compensation - Su_5

Stock-Based Compensation - Summary of Activity of Restricted Stock Units (Detail) - Restricted Stock Units [Member]	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted stock units outstanding, Unvested beginning balance | shares	571,303
Number of restricted stock units outstanding, Granted | shares	1,077,600
Number of restricted stock units outstanding, Vested | shares	(181,248)
Number of restricted stock units outstanding, Forfeited | shares	(61,613)
Number of restricted stock units outstanding, Unvested ending balance | shares	1,406,042
Weighted-average grant date fair value, Unvested beginning balance | $ / shares	$ 6.15
Weighted-average grant date fair value, Granted | $ / shares	1.26
Weighted-average grant date fair value, Vested | $ / shares	6.38
Weighted-average grant date fair value, Forfeited | $ / shares	5.55
Weighted-average grant date fair value, Unvested ending balance | $ / shares	$ 2.4

Stock-Based Compensation - Su_6

Stock-Based Compensation - Summary of Grant Date Fair Value of Restricted Stock Unit Awards Vested (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant-date fair value	$ 539	$ 390	$ 1,156	$ 641

Stock-Based Compensation - Su_7

Stock-Based Compensation - Summary of Stock-Based Compensation Expenses Related to Restricted Stock Units (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 1,323	$ 1,079	$ 1,855	$ (371)
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 453	$ 228	$ 658	$ (521)

Stock-Based Compensation - Su_8

Stock-Based Compensation - Summary of Stock-Based Compensation Granted as Deemed Dividends (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Nonemployee Restricted Stock Units [Member] | Cellectis [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deemed dividends from grants to Cellectis employee	$ 27	$ 107	$ 64	$ 28

Stock-Based Compensation - Perf

Stock-Based Compensation - Performance Stock Units - Additional Information (Detail)	1 Months Ended	6 Months Ended
	Jul. 31, 2021 Day	Jun. 30, 2022 USD ($) shares	Jul. 07, 2021 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance stock, shares granted		2,621,614
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance stock, shares granted		2,961,677
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to performance stock units | $		$ 1,300
Unrecognized stock-based compensation expense, expected recognition weighted-average period		25 months
Performance Stock Units [Member] | 2021 Grant | Inducement Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Consecutive trading day | Day	30
Performance Stock Units [Member] | 2021 Grant | Mr Carr [Member] | 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance stock, shares granted		530,000
Performance Stock Units [Member] | 2021 Grant | Mr Carr [Member] | Inducement Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance stock, shares granted			600,000

Share Based Compensation- Summa

Share Based Compensation- Summary Of Share Based Compensation Performance Shares Award Outstanding Activity (Detail) - Performance Stock Units [Member]	6 Months Ended
	Jun. 30, 2022 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding as of December 31, 2021:	745,000
Issued	530,000
Forfeited/canceled	(145,000)
Exercised	0
Outstanding as of June 30, 2022:	1,130,000

Stock-Based Compensation - Su_9

Stock-Based Compensation - Summary of Stock-Based Compensation Expenses Related to Performance Stock Units (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 1,323	$ 1,079	$ 1,855	$ (371)
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 161	$ 51	$ 307	$ (255)

Leases, Commitments, and Cont_3

Leases, Commitments, and Contingencies - Additional Information (Detail) $ in Millions	Jun. 30, 2022 USD ($) ft²
Roseville, MN Lease [Member]
Other Commitments [Line Items]
Lessee, Operating Lease, Remaining Lease Term	15 years 9 months 18 days
Maximum [Member] | Roseville, MN Lease [Member]
Other Commitments [Line Items]
Lessee, Operating Lease, Remaining Lease Term	5 years
Corporate Headquarters [Member]
Other Commitments [Line Items]
Office and lab building area | ft²	38,000
Equipment [Member]
Other Commitments [Line Items]
Restricted cash | $	$ 0.6

Leases, Commitments, and Cont_4

Leases, Commitments, and Contingencies - Schedule Of Impact Of Adoption Of The Standard On Consolidated Balance Sheet (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Jan. 01, 2022	Dec. 31, 2021
Assets
Land, buildings, and equipment	$ 5,077		$ 21,731
Operating lease right-of-use assets	13,855		0
Liabilities and stockholders' equity
Current portion of financing lease obligations	246		370
Other current liabilities	413		191
Financing lease obligations	37		17,506
Operating lease obligations	13,652		0
Accumulated deficit	$ (203,364)		(196,092)
Accounting Standards Update 2016-02 [Member]
Assets
Operating lease right-of-use assets		$ 14,100
Liabilities and stockholders' equity
Operating lease obligations		$ 14,100
Cumulative Effect, Period of Adoption, Adjusted Balance [Member] | Accounting Standards Update 2016-02 [Member]
Assets
Land, buildings, and equipment			5,188
Operating lease right-of-use assets			14,090
Total assets			19,278
Liabilities and stockholders' equity
Current portion of financing lease obligations			366
Other current liabilities			467
Financing lease obligations			135
Operating lease obligations			13,814
Accumulated deficit			(195,260)
Total liabilities and stockholders' equity			(180,478)
Previously Reported [Member] | Accounting Standards Update 2016-02 [Member]
Assets
Land, buildings, and equipment			21,731
Operating lease right-of-use assets			0
Total assets			21,731
Liabilities and stockholders' equity
Current portion of financing lease obligations			370
Other current liabilities			191
Financing lease obligations			17,506
Operating lease obligations			0
Accumulated deficit			(196,092)
Total liabilities and stockholders' equity			(178,025)
Revision of Prior Period, Accounting Standards Update, Adjustment [Member] | Accounting Standards Update 2016-02 [Member]
Assets
Land, buildings, and equipment			(16,543)
Operating lease right-of-use assets			14,090
Total assets			(2,453)
Liabilities and stockholders' equity
Current portion of financing lease obligations			(4)
Other current liabilities			276
Financing lease obligations			(17,371)
Operating lease obligations			13,814
Accumulated deficit			832
Total liabilities and stockholders' equity			$ (2,453)

Leases, Commitments, and Cont_5

Leases, Commitments, and Contingencies - Summary of Non Cancellable Operating Leases (Detail) $ in Thousands	Jun. 30, 2022 USD ($)
Disclosure of Non Cancellable Operating Leases [Line Items]
Right-of-Use Asset	$ 13,852
Roseville, MN Lease [Member]
Disclosure of Non Cancellable Operating Leases [Line Items]
Remaining Term (years)	15 years 9 months 18 days
Right-of-Use Asset	$ 13,852

Leases, Commitments, and Cont_6

Leases, Commitments, and Contingencies - Summary of Lease Cost (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022
Lease, Cost [Abstract]
Finance Lease cost	$ 7	$ 16
Operating lease cost	394	793
Variable lease cost	227	458
Total	$ 628	$ 1,267

Leases, Commitments, and Cont_7

Leases, Commitments, and Contingencies - Summary of Other Information Related to Leases (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows, Operating	$ 135
Operating cash flows, Financing	0
Financing cash flows, Operating	0
Financing cash flows, Financing	$ 190
Operating Lease, Weighted average remaining lease term (years)	15 years 9 months 18 days
Finance Lease, Weighted average remaining lease term (years)	6 months
Operating Lease, Weighted average discount rate	7.90%
Finance Lease, Weighted average discount rate	8.10%

Leases, Commitments, and Cont_8

Leases, Commitments, and Contingencies - Summary of Future Minimum Rental Payments (Detail) $ in Thousands	Jun. 30, 2022 USD ($)
Schedule of Future Minimum Rental Payments [Abstract]
Operating, Remainder of 2022	$ 689
Operating, 2023	1,446
Operating, 2024	1,480
Operating, 2025	1,479
Operating, 2026	1,479
Operating, 2027	1,479
Operating, Thereafter	16,991
Total Operating	25,043
Operating, Less: imputed interest	(11,088)
Total	13,955
Financing, Remainder of 2022	258
Financing, 2023	38
Financing, 2024	0
Financing, 2025	0
Financing, 2026	0
Financing, 2027	0
Financing, Thereafter	0
Total Financing	296
Financing, Less: imputed interest	(13)
Total	283
Remainder of 2022	947
2023	1,484
2024	1,480
2025	1,479
2026	1,479
2027	1,479
Thereafter	16,991
Total	25,339
Less: imputed interest	(11,101)
Total	$ 14,238

Supplemental Information - Summ

Supplemental Information - Summary of Certain Statements of Operations Amounts (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expenses	$ 1,323	$ 1,079	$ 1,855	$ (371)
Interest expense	(6)	(359)	(16)	(719)
Interest income	12	2	13	16
Common stock warrants - financing costs amortization	(22)	0	(30)	0
Total	(16)	(357)	(33)	(703)
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expenses	380	417	410	809
Selling, General, and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expenses	$ 943	$ 662	$ 1,445	$ (1,180)

Supplemental Information - Su_2

Supplemental Information - Summary of Certain Balance Sheet Amounts (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Condensed Balance Sheet Statements Captions [Line Items]
Cash and cash equivalents		$ 11,316	$ 13,823
Restricted cash	$ 500	545	499
Non-current restricted cash		53	99
Total		$ 11,914	$ 14,421

Supplemental Information - Su_3

Supplemental Information - Summary of Statements of Certain Statements of Cash Flows Amounts (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Condensed Financial Information Disclosure [Abstract]
Interest paid	$ 14	$ 716
Receivable from Jefferies for shares issued under ATM Facility	(260)	0
Non-cash additions to land, buildings, and equipment	(618)	0
Unpaid stock offering costs included in stockholders' equity	1	0
Cumulative effect of adoption of lease accounting standard on stockholders' equity	832	0
Establishment of right-to-use assets and associated operating lease liabilities	$ 14,090	$ 0